Overview

Optimized Antithrombotic Therapy of Acute Myocardial Infarction With Left Ventricular Mural Thrombus

Status:
Not yet recruiting

Trial end date:
2022-06-01

Target enrollment:
0

Participant gender:
All

Summary

A multi-center study will be done to explore the optimal regimen of antithrombotic therapy for acute myocardial infarction with left ventricular mural thrombus. The investigators will evaluate the different combinations of antiplatelet drugs and anticoagulants for at least one month, such as aspirin 100mg qd+clopidogrel 75mg qd+warfarin (INR1.8-2.2), aspirin 100mg qd+clopidogrel 75mg qd+dabigatran 110mg bid, aspirin 100mg qd+ticagrelor 60mg bid+warfarin (INR1.8-2.2), and aspirin 100mg qd+ticagrelor 60mg bid+dabigatran 110mg bid. Transthoracic two-dimensional echocardiography will be done at the 1-month, 3-month and 6-month follow-ups to evaluate the left ventricular mural thrombus and determinate whether the antithrombotic therapy regimen could be regulated to double antiplatelet or anticoagulant+clopidogrel 75mg qd/ticagrelor 60mg bid. Then the investigators will complete the 12-month follow-up to evaluate the efficacy and safety of the optimal antithrombotic therapy regimen for acute myocardial infarction with left ventricular mural thrombus.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

The First Affiliated Hospital with Nanjing Medical University

Treatments:

Adenosine
Anticoagulants
Aspirin
Clopidogrel
Dabigatran
Platelet Aggregation Inhibitors
Ticagrelor
Ticlopidine
Warfarin

Criteria

Inclusion Criteria:

- acute myocardial infarction with left ventricular mural thrombus

Exclusion Criteria:

- BARC bleedings ≥ 2

- atrial fibrillation

- acute stroke or other systemic circulation embolism